Big Pharma Has Rediscovered the Anti-Infectives Market and Is Bolstering Its Pipelines Through Licensing Agreements And Acquisitions - More Inside Infectious Diseases Report.DUBLIN -- Research and Markets(http://www.researchandmarkets.com/reports/c40815) has announced the addition of Infectious Diseases infectious diseases: see communicable diseases. : R&D Challenges and Market Drivers to their offering. Global sales of anti-infective drugs reached $44.5 billion in 2005 and will likely double over the next 5 years. Antibiotics led the category at $31 billion. Infectious Diseases: R&D Challenges and Market Drivers, this new report, analyzes the factors driving infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. therapeutic and diagnostic markets, the key business and technology trends, targets and drugs in development, companies at the forefront of anti-infective R&D, and the commercial opportunities and challenges of anti-infective drugs and vaccines. Past hurdles to pursuing anti-infective drug development including historically low margins, short therapeutic regimens, manufacturing challenges, and regulatory problems associated with developing drugs for "unvalidated" microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. targets are no longer discouraging entrants. Big Pharma has rediscovered the anti-infectives market and is bolstering its pipelines through licensing agreements and acquisitions. And smaller, less risk-aversive biopharmaceutical companies have discovered the allure of substantial profits while also meeting public health goals. A quantitative survey (commissioned by the author in July/August 2006) of individuals involved in infectious disease R&D and business development sheds light on the research priorities and R&D trends in industry, government, and academia. The evolution of drug resistance is the most powerful driver of anti-infective R&D. Other factors fuelling research that are assessed in the report include: - The emergence of pandemics - Perceived and actual threat of bioterrorism - Advances in molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller and nanotechnology - Accumulating evidence that many chronic diseases have an infectious etiology Infectious Diseases: R&D Challenges and Market Drivers drills down into the emerging commercial opportunities, providing expert insight into: - Recent developments and opportunities in the infectious disease testing market, which accounts for 80% of the estimated $6.5 billion global molecular diagnostics market - The vaccines market, which has shed its low-margin image and posted -fold growth over the past decade driven by new threats, new technologies, and new targets - Food safety and the food microbiology testing market - The expanding market for veterinary drugs and diagnostics - Niche opportunities in antimicrobial resistance - Opportunities--and a practical guide to capitalizing on them--in Biodefense - Neglected disease markets both large and small, including Malaria, TB, Onchocerciasis onchocerciasis /on·cho·cer·ci·a·sis/ (-ser-ki´ah-sis) infection by nematodes of the genus Onchocerca. Parasites invade the skin, subcutaneous tissues, and other parts of the body, producing fibrous nodules; blindness occurs after , Dengue dengue or breakbone fever or dandy fever Infectious, disabling mosquito-borne fever. Other symptoms include extreme joint pain and stiffness, intense pain behind the eyes, a return of fever after brief pause, and a characteristic rash. , and more. - Individuals in R&D, business development, strategic planning, and marketing will benefit from the hundreds of hours of primary and secondary research that went into Infectious Diseases: R&D Challenges and Market Drivers. About the Author: Leslie A. Pray, Ph.D., is a science writer and consultant to the Forum on Microbial Threats at the National Academy of Sciences. She has written extensively on a range of genetic, biotechnology, infectious disease, public health policy, and higher education issues for The Scientist, Genomics and Proteomics, The Chronicle of Higher Education, Orion, the American Chemical Society The American Chemical Society (ACS) is a learned society (professional association) based in the United States that supports scientific inquiry in the field of chemistry. Founded in 1876 at New York University, the ACS currently has over 160,000 members at all degree-levels and in , the American Association for the Advancement of Science American Association for the Advancement of Science (AAAS), private organization devoted to furthering the work of scientists and improving the effectiveness of science in the promotion of human welfare. , Oak Ridge National Laboratory Oak Ridge National Laboratory (ORNL) is a multiprogram science and technology national laboratory managed for the United States Department of Energy by UT-Battelle, LLC. ORNL is located in Oak Ridge, Tennessee, near Knoxville. , and the CBR (1) (Computer-Based Reference) Reference materials accessible by computer in order to help people do their jobs quicker. For example, this database on disk! (2) (Constant Bit Rate) A uniform transmission rate. Institute for Biomedical Research, among others. Dr. Pray received her Ph.D. in population genetics Population genetics The study of both experimental and theoretical consequences of mendelian heredity on the population level, in contradistinction to classical genetics which deals with the offspring of specified parents on the familial level. from the University of Vermont and her B.A. degree from the University of California, Berkeley The University of California, Berkeley is a public research university located in Berkeley, California, United States. Commonly referred to as UC Berkeley, Berkeley and Cal . An elected member of Sigma Xi, she has been the recipient of numerous scientific research awards, including an American Society of Naturalists The American Society of Naturalists was founded in 1883 and is one of the oldest professional societies dedicated to the biological sciences in North America. The purpose of the Society is "to advance and diffuse knowledge of organic evolution and other broad biological principles so as Young Investigator Award and a National Science Foundation Environmental Biology Postdoctoral Fellows. Topics Include: NEW MICROBIAL DEMANDS AND MAJOR DRIVERS OF THE ANTI-INFECTIVE MARKETPLACE THERAPEUTIC CHALLENGES: MICROBES AS MOVING TARGETS DOING THE DETECTIVE WORK: INFECTIOUS DISEASE DIAGNOSTICS COMMERCIAL OPPORTUNITIES: COMFORTABLE NICHES EXIST FOR BOTH BIG PHARMA AND SMALL BIOTECHS COMPANY PROFILES Acambis Adlyfe Inc. Akonni Biosystems Alnylam Pharmaceuticals Arbor Vita Corporation Biophage Pharma Inc. CEL-SCI Corporation CombiMatrix Corporation Cubist Pharmaceuticals, Inc. Gilead Sciences, Inc. NanoBio Corporation Nanosphere, Inc. Obetech, LLC Panacos Pharmaceuticals, Inc. PowderMed Limited Progenics Pharmaceuticals, Inc. Ribomed Biotechnologies, Inc. Tanox, Inc. Targanta Therapeutics, Inc. Tm Bioscience Corporation References Glossary Company Index with Web Sites Tables and Figures For more information visit http://www.researchandmarkets.com/reports/c40815 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion